Artificial intelligence is set to revolutionize the Indian pharmaceutical sector, with AI adoption potentially adding 3-4 percentage points to profit margins by 2035, according to latest Bernstein analysis. The brokerage's proprietary model simulated AI use cases across research and development, manufacturing operations, quality systems, and field force functions, estimating that R&D and manufacturing operations could account for nearly 70% of the AI-led profitability gains. This technological transformation comes as Indian biopharma enters what Bernstein calls an 'innovation power decade', positioning the sector to create value through specialty medicines and incremental innovation rather than attempting to replicate global pharmaceutical giants' new-molecule discovery models. According to Nandan Kulkarni, Director at Bernstein, the sector appears to have bottomed out in FY26 and is now poised for a long-term rerating, supported by structural changes in the global healthcare landscape and increasing investments in research and development.
Indian pharmaceutical companies are undergoing a fundamental transformation from generics-focused manufacturers to innovation-driven biopharma players, with this transition extending through 2035. According to Nandan Kulkarni, Director at Bernstein, the industry is transforming into an 'innovation play from its historic pure US-centric generics play', which will be an important driver of earnings moving forward. Indian companies are allocating greater financial and intellectual capital towards innovation, specialty drugs, orphan therapies, and complex biologics, which could significantly improve profitability over the coming years. The transformation is being driven by global regulatory frameworks moving in India's favor, with pathways around contract development and manufacturing organizations, specialty therapies, and orphan drug designations creating meaningful new opportunities that did not exist at scale even five years ago. Discussions across corporate boardrooms are increasingly shifting from generic opportunities to new drug applications (NDAs), 505(b)(2) products, specialty medicines and innovation-focused pipelines.
Investment bank Bernstein has issued 'Outperform' ratings for Sun Pharma, Cipla, Dr. Reddy's, and Gland Pharma for 2023, as reported by ET Now. The brokerage believes these companies are well-positioned to manage ongoing price erosion in the US market while also benefiting from a return to volume growth in India's domestic market. This positive outlook is based on improving raw material costs and operating leverage, which are expected to enhance margins after a challenging 2022. Bernstein expects the top 10 pharmaceutical companies to command nearly 50% of the domestic market by 2030, with the brokerage believing investors continue to underappreciate the earnings potential of the Indian pharmaceutical sector.
According to ET Now reports, Bernstein has issued specific target prices for major pharma stocks with significant upside potential. Zydus Lifesciences leads with a target price of ₹1,457, representing a 34% upside from its current price of ₹1,084.60. Lupin is projected to reach ₹2,707, offering a 19% upside from its current ₹2,267.00 price. Sun Pharma targets ₹2,235, providing a 24% upside from its current ₹1,800.50 price. The brokerage maintains cautious views on Mankind Pharma and Biocon, rating them as underperformers with potential downsides of 13% and 22% respectively. Aurobindo Pharma receives a 'Market-Perform' rating with a target of ₹1,498, offering a 6% upside from its current ₹1,402.00 price.
The pharmaceutical sector is experiencing significant opportunities in GLP-1 drugs and supply chain diversification, which present substantial growth potential. According to Bernstein's latest analysis, the brokerage estimates these innovation categories together represent a roughly $400 billion global opportunity and could add $70-75 billion in revenues to the Indian biopharma industry over the next decade. These opportunities include 505(b)(2) products, orphan drugs, drug-device combinations, drug repurposing, GLP-1 and other metabolic peptides, as well as RNA- and cell-based therapies such as CAR-T. Bernstein calls these 'Rainmakers' as they have a potential to add meaningful revenues in the range of $100 million-500 million and high teen percentage return on R&D investments. The brokerage projects the Indian biopharma industry will grow from about $57 billion in FY25 to nearly $195 billion by 2035, implying a 13% compound annual growth rate compared with industry consensus estimates of around 10%.
The US generics market is experiencing a normalization of price erosion that had been severe in 2021, with improvements in injectable approvals and a reduction in inventory challenges. Companies are expected to benefit from a more stable pricing environment, and the entry of complex molecules into the generics space could provide significant opportunities for growth. As reported by ET Now, the market has yet to fully price in key growth catalysts including incremental 'Rainmaker' revenues, accelerating expansion across Europe and other international markets (EMEA), and margin improvements driven by AI-led productivity gains. The Bernstein analysis suggests that building incremental innovation pathways that produce Rainmakers provides the highest return per rupee of invested capital, as Indian drugmakers continue to lag global innovators in areas such as R&D programme efficiency, clinical development and specialized commercialization capabilities. Research and development investments are becoming the key differentiator among Indian pharmaceutical companies, with future winners expected to be firms that build global capabilities, acquire promising early-stage assets and successfully commercialise innovative products.
